BLA 020744 · Chiesi USA INC
Curosurf
Poractant Alfa · Intratracheal · Surfactant
NovelOrphanLast checked: Nov 20, 2026Latest source record: May 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Nov 18, 1999
Approved uses
2
Original approval plus efficacy supplements
Registered trials
38
7 Phase 3, 4 recruiting
FAERS reports
737
685 serious, 222 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 10, 2025.
CUROSURF ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS. CUROSURF is a surfactant indicated for the rescue treatment, including the reduction of mortality and pneumothoraces, of Respiratory Distress Syndrome (RDS) in premature infants. ( 1 )
Mechanism: Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in Respiratory Distress Syndrome (RDS) characterized by poor lung expansion, inadequate gas exchange, and a gradual collapse of the lungs (atelectasis). CUROSURF compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 2002 Supplement 4 · Efficacy Letter
- Nov 18, 1999 Original approval · Type 1 - New Molecular Entity LabelReviewLetter
1 products under this application
- CUROSURF · PORACTANT ALFA 80MG/ML · SUSPENSION, INTRATRACHEAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Poractant Alfa" as an intervention, any sponsor and status, largest first.
- The Budesonide in Babies (BiB) TrialPivotal-lookingActive, not recruiting
NICHD Neonatal Research NetworkResearch network
NCT04545866 · 642 participants · Start Apr 1, 2021 · Primary completion Sep 5, 2024
Drug: budesonide (Pulmicort nebulizing suspension).; surfactant (poractant alfa;Curosurf) · For: Bronchopulmonary Dysplasia (BPD); Respiratory Distress Syndrome; Prematurity; Extreme and 1 more
Sites: Birmingham, Alabama; Palo Alto, California; San Diego, California · 19 sites in all
- A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm InfantsPivotal-lookingCompleted
University of Sao PauloAcademic, hospital or other
NCT02305160 · 327 participants · Start Apr 2005 · Primary completion May 2006
Drug: Butantan; Control · For: Respiratory Distress Syndrome
Sites: Vitória da Conquista, Brazil; Brasília, Brazil; Goiânia, Brazil · 30 sites in all
- Intratracheal Budesonide/Surfactant Prevents BPDPivotal-lookingCompleted
Taipei Medical UniversityAcademic, hospital or other
NCT03275415 · 310 participants · Start Jul 1, 2019 · Primary completion Jun 30, 2022
Drug: budesonide; Saline · For: Respiratory Distress Syndrome; Bronchopulmonary Dysplasia
Sites: Taipei, Taiwan
- Curosurf/Budesonide for Infants With Respiratory Distress SyndromePivotal-lookingCompleted
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityAcademic, hospital or other
NCT02013115 · 300 participants · Start Jan 1, 2015 · Primary completion Oct 30, 2017
Drug: Budesonide · For: Respiratory Distress Syndrome
Sites: Chongqing, China
- Non Inferiority Trial Investigating Surfactants Administered Via MISTPivotal-lookingRecruiting
Endeavor HealthAcademic, hospital or other
NCT06074380 · 262 participants (planned) · Start Jan 1, 2024 · Primary completion Dec 30, 2025
Drug: MIST surfactant · For: Respiratory Distress Syndrome
Sites: Evanston, Illinois
- Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress SyndromePivotal-lookingRecruiting
Uludag UniversityAcademic, hospital or other
NCT07350018 · 234 participants (planned) · Start Jan 20, 2026 · Primary completion Feb 20, 2027
Drug: Poractant alfa; Calfactant · For: Respiratory Distress Syndrome in Premature Infants; Respiratory Distress Syndrome (RDS); Surfactant
Sites: Bursa, Turkey (Türkiye) · 5 sites in all
- Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 WeeksPivotal-lookingCompleted
University of CologneAcademic, hospital or other
NCT00751959 · 213 participants · Start Apr 2009 · Primary completion Jun 2012
Drug: Curosurf; Curosurf · For: Respiratory Distress Syndrome, Newborn
Sites: Aschaffenburg, Germany; Berlin, Germany; Bochum, Germany · 13 sites in all
- Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap StudyPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT00501982 · 208 participants · Start Mar 2007 · Primary completion May 2008
Drug: Poractant alfa (Curosurf®) · For: Respiratory Distress Syndrome, Newborn
Sites: Prague, Czechia; Marseille, France; Bologna, Italy · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neonatal hypoxia121
- off label use84
- pulmonary haemorrhage78
- bradycardia neonatal51
- ill-defined disorder50
- drug ineffective46
- product complaint40
- endotracheal intubation complication39
- pneumothorax37
- infantile apnoea30
- neonatal respiratory failure28
- pulmonary haemorrhage neonatal28
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 4 |
| 2006 | 16 |
| 2007 | 16 |
| 2008 | 12 |
| 2009 | 8 |
| 2010 | 9 |
| 2011 | 4 |
| 2012 | 13 |
| 2013 | 16 |
| 2014 | 11 |
| 2015 | 15 |
| 2016 | 18 |
| 2017 | 31 |
| 2018 | 145 |
| 2019 | 68 |
| 2020 | 109 |
| 2021 | 41 |
| 2022 | 54 |
| 2023 | 42 |
| 2024 | 56 |
| 2025 | 16 |
| 2026 | 28 |
Recalls
1 FDA enforcement reports for this application.
Mar 17, 2026 · Class II · Ongoing
Lack of Assurance of Sterility
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.
Manley BJ, Kamlin COF, Donath SM, et al. · JAMA 2024 · Clinical Trial, Phase III, Multicenter Study
- Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.
Ambalavanan N, Carlo WA, Nowak KJ, et al. · JAMA 2025 · Clinical Trial, Phase III, Multicenter Study
- Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials.
Sánchez Luna M, Bacher P, Unnebrink K, et al. · J Perinatol 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial.
Dargaville PA, Kamlin COF, Orsini F, et al. · JAMA 2023 · Multicenter Study, Randomized Controlled Trial
- European multicenter trials of curosurf for treatment of neonatal respiratory distress syndrome.
Robertson B · Lung 1990 · Clinical Trial, Multicenter Study
- Lung Lavage with Dilute Surfactant vs. Bolus Surfactant for Meconium Aspiration Syndrome.
Arayici S, Sari FN, Kadioglu Simsek G, et al. · J Trop Pediatr 2019 · Comparative Study, Randomized Controlled Trial
Sponsor: Chiesi USA INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.